ARAntonia Resag

Antonia Resag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonia Resag has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Granzyme B + T Cell Infiltration Distinguishes Cutaneous Squamous Cell Carcinoma From Actinic Keratosis

    by Antonia Resag, Marina Wanner, Christoph H. Tripp, Luise Rupp, Daniela Ortner, Selina Neurauter, Barbara Del Frari, Nina Frischhut, Van Anh Nguyen, Marc Schmitz, et al.

  • Open Access

    Targeting Langerhans cells using a modular mannosylated nucleic acid-based vaccine platform

    by Simon Christian Vinther, Antonia Resag, Karina Thao Thu Le, Claudia Christine Zelle-Rieser, Helen Strandt, Mette Galsgaard Malle, Stig Hill Christiansen, Barbara Del Frari, Theresia Stigger, Bastian Schilling, et al.

    The skin is a diverse reservoir of immune cells with strong potential for immunotherapeutic delivery. Langerhans cells (LCs) in the epidermis are antigen-presenting cells, accessible for vaccination using carbohydrate-conjugated therapeutics targeting their endocytic lectin receptor, Langerin. As carbohydrate-lectin binding is highly dependent on valency, scaffolds that enable control over ligand spacing and stoichiometry are instrumental in enhancing receptor binding and selectivity. Here we utilized a self-assembled nucleic acid-based Holliday Junction scaffold, fully modified for nuclease protection and with a well-defined carbohydrate arrangement to optimize drug delivery to LCs. In vitro screening with Langerin-expressing cells revealed that mannosylated Holliday Junctions showed the strongest binding. This was confirmed in human epidermal cell suspensions, demonstrating specificity and valency-driven interactions. Topical administration of mannosylated scaffolds on skin explants enabled effective targeting of epidermal LCs. Finally, in an antigen-presentation assay, in vitro differentiated LCs loaded with mannosylated and peptide-conjugated scaffolds significantly enhanced T cell activation. Overall, our study presents a promising nucleic acid-based platform for precise LC targeting and drug delivery, with broad potential for skin-directed immunotherapies.

  • Open Access

    The Immune Contexture of Liposarcoma and Its Clinical Implications

    by Antonia Resag, Giulia Toffanin, Iva Benešová, Luise Müller, Vlatko Potkrajcic, Andrej Ozaniak, Robert Lischke, Jirina Bartunkova, Antonio Rosato, Korinna Jöhrens, et al.

    Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid pleomorphic LPS. They display variations in genetic alterations, clinical behavior, and prognostic course. While accumulating evidence implicates a crucial role of the tumor immune contexture in shaping the response to anticancer treatments, the immunological landscape of LPS is highly variable across different subtypes. Thus, DDLPS is characterized by a higher abundance of infiltrating T cells, yet the opposite was reported for MLPS. Interestingly, a recent study indicated that the frequency of pre-existing T cells in soft tissue sarcomas has a predictive value for immune checkpoint inhibitor (CPI) therapy. Additionally, B cells and tertiary lymphoid structures were identified as potential biomarkers for the clinical outcome of LPS patients and response to CPI therapy. Furthermore, it was demonstrated that macrophages, predominantly of M2 polarization, are frequently associated with poor prognosis. An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches. Here, we summarize recent studies focusing on the clinicopathological, genetic, and immunological determinants of LPS.